Recombinant full-length parathyroid hormone (1-84): profile report.
Moen
Marit D
MD
Wolters Kluwer Health / Adis, Auckland, New Zealand. demail@adis.co.nz
Scott
Lesley J
LJ
D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000517:prevention & control*; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D010281:Parathyroid Hormone; D011994:Recombinant Proteins